Sugi Predict

Sugi Predict / Compounds / SCHEMBL2845141

SCHEMBL2845141

SCHEMBL2845141

C[C@H](Nc1nc2ccc(Oc3cc(-n4cncn4)ccn3)cc2s1)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 11/20 0.41
▸ PI4KA P42356 2/20 0.41
▸ PI4KB Q9UBF8 2/20 0.41
▸ PIP5K1C O60331 1/20 0.41
▸ PIK3CG P48736 1/20 0.41
▸ NPC1 O15118 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ PDGFRB P09619 2/20 0.37
▸ KIT P10721 2/20 0.37
▸ PDGFRA P16234 2/20 0.37
▸ FLT3 P36888 2/20 0.37
▸ USP30 Q70CQ3 2/20 0.37
▸ HCRTR1 O43613 1/20 0.36
▸ MAPK14 Q16539 1/20 0.35
▸ ITK Q08881 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845143 1.00 CSF1R (0.41) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2843310 0.88 PI4KA (0.41) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2843313 0.88 PI4KA (0.41) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2848900 0.85 PI4KA (0.41) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2848892 0.85 PI4KA (0.41) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2843486 0.84 CSF1R (0.42) CSF1RPI4KAPI4KBPIK3CGNPC1
SCHEMBL2846296 0.79 CSF1R (0.46) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2846300 0.79 CSF1R (0.46) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2852429 0.79 NPC1 (0.44) CSF1RPI4KAPI4KBPIP5K1CPIK3CG
SCHEMBL2852428 0.79 NPC1 (0.44) CSF1RPI4KAPI4KBPIP5K1CPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885PI4KA 2704/4885PI4KB 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.